Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(166 produits)
- Bcr-Abl(117 produits)
- EGFR(551 produits)
- FAK(72 produits)
- FLT(88 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(176 produits)
- JAK(243 produits)
- PDGFR(127 produits)
- RAAS(86 produits)
- Src(82 produits)
- Syk(37 produits)
- Thrombine(51 produits)
- VDA(2 produits)
- VEGFR(236 produits)
Affichez 6 plus de sous-catégories
2270 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
JAK2/FLT3-IN-1 TFA
JAK2/FLT3-IN-1 (TFA), an oral JAK2/FLT3 inhibitor, shows anticancer properties; IC50: JAK2 (0.7 nM), FLT3 (4 nM), JAK1 (26 nM), JAK3 (39 nM).Formule :C27H35F4N7O3Couleur et forme :SolidMasse moléculaire :581.61VEGFR-IN-3
CAS :VEGFR-IN-3 inhibits cancer cell growth (OVCAR-4, MDA-MB-468) with IC50s: 0.29, 0.35μM. Used in cancer research.Formule :C27H28N2O6Couleur et forme :SolidMasse moléculaire :476.52HER2-IN-21
CAS :HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.
Formule :C20H18N4O3SCouleur et forme :SolidMasse moléculaire :394.447HER2-IN-12
HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.Formule :C17H18BrN5O2SCouleur et forme :SolidMasse moléculaire :436.33JAK-2/3-IN-3
JAK-2-/3-IN-3 (ST4j) is a potent JAK2/3 inhibitor for leukemia research, with IC50s: JAK2, 13 nM; JAK3, 14.86 nM; induces apoptosis.Formule :C13H10Cl2N4O2Couleur et forme :SolidMasse moléculaire :325.15GLPG3312
CAS :GLPG3312 is a selective and potent pan-SIK inhibitor with the advantage of oral activity, for SIK1, SIK2 and SIK3, anti-inflammatory and immunomodulatory .Formule :C23H21F2N5O3Degré de pureté :98.53%Couleur et forme :SolidMasse moléculaire :453.44VEGFR/PDGFR-IN-1
CAS :VEGFR/PDGFR-IN-1 (Compound 1) is an inhibitor of VEGFR with an IC50 of 0.4 μM. It can inhibit angiogenesis in HUVEC cells and holds promise for impeding tumor growth and metastasis.Formule :C17H21N5O3Couleur et forme :SolidMasse moléculaire :343.38TZEP7
CAS :TZEP7 functions as an EGFR kinase inhibitor in cancer cells. It exhibits cytotoxicity and induces apoptosis within these cells. TZEP7 downregulates the anti-apoptotic protein Bcl-2, upregulates the pro-apoptotic protein Bax, and increases caspase levels. This compound holds potential for research in anticancer drug development.Formule :C27H19ClFNSCouleur et forme :SolidMasse moléculaire :443.963Tofacitinib Prodrug-1
Tofacitinib Prodrug-1: an oral prodrug reducing Tofacitinib's side effects, treats ulcerative colitis in mice effectively with low toxicity.Formule :C36H39ClN10O7Couleur et forme :SolidMasse moléculaire :759.21FGFR1 inhibitor-17
CAS :FGFR1inhibitor-17 (Compound 92) is a potent inhibitor of FGFR1, with promising applications in cancer research.Formule :C16H13ClN2O3Couleur et forme :SolidMasse moléculaire :316.739VEGFR-2/DHFR-IN-1
Compound 8b inhibits VEGFR-2/DHFR, combats various bacteria, and fights cancer cells.Formule :C20H18ClNO4Couleur et forme :SolidMasse moléculaire :371.81EGFR-IN-47
EGFR-IN-47: strong oral EGFRL858R/T790M/C797S blocker, induces cell death; promising for NSCLC research. IC50: 0.01 μM.Formule :C29H35N7Couleur et forme :SolidMasse moléculaire :481.64TrxR/EGFR-IN-1
CAS :TrxR/EGFR-IN-1 (Compound L1Au2) is a TrxR/EGFR inhibitor with activity against both gefitinib-sensitive and -resistant lung cancer, effectively suppressing tumor proliferation and promoting apoptosis. It enhances GPX4 degradation through autophagosome-lysosome and proteasome pathways, leading to ferroptosis. Additionally, it induces endoplasmic reticulum stress and triggers immunogenic cell death, making it applicable for studies on gefitinib-resistant lung cancer.Formule :C24H24AuClFN6O2PCouleur et forme :SolidMasse moléculaire :710.878VEGFR-2-IN-18
VEGFR-2-IN-18 is a potent VEGFR-2 inhibitor with a 60 nM IC50, promoting cell apoptosis and anticancer effects.Formule :C20H13ClN4O2Couleur et forme :SolidMasse moléculaire :376.8AKN-028 acetate
AKN-028 acetate: an oral TK inhibitor for AML research, targets FLT3 with IC50 of 6 nM, inhibits autophosphorylation, and induces apoptosis.Formule :C19H18N6O2Couleur et forme :SolidMasse moléculaire :362.39EGFR/HER2-IN-4
EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.Couleur et forme :SolidHDAC-IN-35
HDAC-IN-35 (Compound 14) is an effective and selective inhibitor of VEGFR-2 and HDAC, with IC50 values of 13.2 and 0.166 μM for VEGFR-2 and HDAC6, respectively.Formule :C17H13ClF3N3O3Couleur et forme :SolidMasse moléculaire :399.75JAK3-IN-11
CAS :JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.Formule :C23H23N5O2Couleur et forme :SolidMasse moléculaire :401.46T-1-PMPA
CAS :T-1-PMPA, a potent EGFR inhibitor, demonstrates apoptotic properties and effectively inhibits EGFR WT and EGFR 790m, with IC50 values of 86 nM and 561.73 nM, respectively [1].Formule :C16H17N5O3Couleur et forme :SolidMasse moléculaire :327.34EGFR/HER2-IN-5
EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.Couleur et forme :SolidSJ1008066
CAS :SJ1008066 is a MAGE-A11 inhibitor with an IC50 of 0.13 μM. It binds to the MAGE homology domain (MHD) and disrupts the MAGE-A11:PCF11 interaction.Formule :C21H22N4Couleur et forme :SolidMasse moléculaire :330.43Tyrosine kinase-IN-9
CAS :Tyrosine kinase-IN-9 (Compound B) is an inhibitor of c-Abl. It is useful for studying neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.Formule :C20H14ClN3O3Couleur et forme :SolidMasse moléculaire :379.796TGF-βRI inhibitor 3
CAS :TGF-βRI inhibitor 3 (Compound 9ac) is a selective inhibitor of TGF-β that effectively suppresses the TGF-β signaling pathway. It exhibits IC50 values of 13 μM for c-Src kinase and 0.63 μM for ALK5 kinase.
Formule :C21H21NO4Couleur et forme :SolidMasse moléculaire :351.396VEGFR-2-IN-17
VEGFR-2-IN-17 (15a) is a potent VEGFR-2 inhibitor with an IC50 of 67.25 nM, showing significant antitumor effects.Formule :C21H14ClN3O2Couleur et forme :SolidMasse moléculaire :375.81VEGFR-2/DHFR-IN-2
VEGFR-2/DHFR-IN-2 inhibits VEGFR-2 & DHFR (IC50: 0.623 & 9.085 μM), toxic to C26, HepG2, MCF7 cells (IC50: 3.59-8.38 μM), promising for cancer study.Formule :C21H21NO4Couleur et forme :SolidMasse moléculaire :351.4M-COPA
CAS :M-COPA disrupts Golgi, blocks MET & Arf1 activation, and inhibits angiogenesis via VEGFR & NF-kB pathways.Formule :C25H34N2O2Couleur et forme :SolidMasse moléculaire :394.55lirucitinib
CAS :Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.Formule :C16H25N5OSCouleur et forme :SolidMasse moléculaire :335.468VEGFR-2-IN-15
VEGFR-2-IN-15 (Compound 14b) is a potent inhibitor of VEGFR-2. VEGFR-2-IN-15 inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.Formule :C23H18ClN3O4SCouleur et forme :SolidMasse moléculaire :467.92LNK01004
CAS :LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.Formule :C26H31N7O2Couleur et forme :SolidMasse moléculaire :473.57JAK1/TYK2-IN-3
JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.Couleur et forme :SolidTAS05567
CAS :TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM).Formule :C21H29N9O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :439.51EGFR/HER2-IN-7
EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.Formule :C19H21N3O2SCouleur et forme :SolidMasse moléculaire :355.45EGFR/VEGFR2-IN-3
CAS :EGFR/VEGFR2-IN-3 (compound 9) is an effective inhibitor of EGFR and VEGFR-2, demonstrating IC50 values of 0.129 µM for EGFR, 0.142 µM for VEGFR-2, and 3.428 µM for COX-2. This compound exhibits cytotoxic properties and induces cell apoptosis (apoptosis) as well as cell cycle arrest at the G2/M phase.Formule :C24H20ClN5O2S2Couleur et forme :SolidMasse moléculaire :510.03GNE-431
CAS :GNE-431: potent, selective noncovalent Btk inhibitor, IC50=3.2 nM; effective against C481R, T474I, T474M mutants, may counter ibrutinib resistance.Formule :C30H32N10O2Couleur et forme :SolidMasse moléculaire :564.64FLT3-ITD-IN-3
CAS :FLT3-ITD-IN-3 (13v) is an orally active inhibitor of FLT3-ITD (internal tandem duplication of FLT3), which works by blocking FLT3 signaling. This inhibition leads to cell cycle arrest in the G0/G1 phase and induces apoptosis. The compound is currently employed in studies related to acute myeloid leukemia (AML).Formule :C27H21ClF2N6O5Couleur et forme :SolidMasse moléculaire :582.943EGFR-IN-147
CAS :EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.Formule :C13H13N5OCouleur et forme :SolidMasse moléculaire :255.275BTK-IN-34
CAS :BTK-IN-34 (compound 9h) functions as a selective BTK inhibitor, exhibiting antiproliferative effects in RAMOS cells by specifically targeting pBTK (Tyr223) while sparing upstream proteins such as Lyn and Syk in the BCR signaling pathway [1].Formule :C22H29N3O4SCouleur et forme :SolidMasse moléculaire :431.55GDC-9918
CAS :GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.Formule :C20H18F2N6O5SCouleur et forme :SolidMasse moléculaire :492.46VEGFR-2-IN-65
CAS :VEGFR-2-IN-65 (Compound 07) functions as a VEGFR-2 inhibitor. It forms hydrogen bonds with Cys180 and can inhibit tube formation in HUVECs.Formule :C21H18N2O3Couleur et forme :SolidMasse moléculaire :346.379JAK-IN-23
"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."Formule :C23H22Cl2N4OCouleur et forme :SolidMasse moléculaire :441.35Milpecitinib
CAS :Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.
Formule :C20H20N4O2SCouleur et forme :SolidMasse moléculaire :380.463KU004
CAS :KU004, a potent dual EGFR/HER2 inhibitor, exhibits anticancer properties. It inhibits the proliferation of human breast cancer SKBR3 cells by inducing G1 phase arrest. KU004 blocks the activation of HER2, EGFR, and the downstream Akt and Erk pathways, primarily inducing apoptosis (Apoptosis) through the extrinsic pathway. Additionally, KU004 is a novel quinazoline derivative.Formule :C29H27ClFN4O2PCouleur et forme :SolidMasse moléculaire :548.98FGFR-IN-5
CAS :FGFR-IN-5 is a potent inhibitor of FGFR. FGFR-IN-5 has potential for research in cancer diseases.Formule :C25H22N6O3Couleur et forme :SolidMasse moléculaire :454.482,5-Di-tert-butyl-1,4-benzoquinone
CAS :2,5-Di-tert-butyl-1,4-benzoquinone is a potent antibacterial agent found primarily in marine Streptomyces sp. VITVSK1, effective against emerging antibiotic resistance. Additionally, it serves as a powerful inhibitor of RNA polymerase.Formule :C14H20O2Couleur et forme :SolidMasse moléculaire :220.31EGFR-IN-126
CAS :EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.Formule :C28H28BrFN4O3Couleur et forme :SolidMasse moléculaire :567.45DA-0157
CAS :DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.Formule :C31H43BrN7O2PCouleur et forme :SolidMasse moléculaire :656.597Tesevatinib tosylate
CAS :Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.Formule :C31H33Cl2FN4O5SCouleur et forme :SolidMasse moléculaire :663.59AJI-214
CAS :AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).Formule :C17H13ClFN5OCouleur et forme :SolidMasse moléculaire :357.772-Methyl-3-phenylquinoxaline
CAS :2-Methyl-3-phenylquinoxaline (compound 38) serves as an effective inhibitor of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase (PDGF-RTK), exhibiting significant inhibitory activity against the full-length PDGFR kinase in intact cells (IC50 greater than 100 μM).Formule :C15H12N2Couleur et forme :SolidMasse moléculaire :220.27NDI-034858
CAS :NDI-034858 (TAK-279) is a tyrosine kinase 2 (TYK2) inhibitor (Kd<200 pM) that targets the JH2 structural domain of Tyk2 for the treatment of autoimmune diseasesFormule :C23H24N8O3Degré de pureté :>99.99%Couleur et forme :SolidMasse moléculaire :460.49Vatalanib hydrochloride
CAS :Vatalanib hydrochloride (PTK787 hydrochloride) is an orally available and highly potent tyrosine kinase (VEGF) inhibitor that reduces the number and size of Aβ plaques in the cortex of 5xFAD mice, which may be useful in the study of Alzheimer's disease and cancer.Formule :C20H16Cl2N4Degré de pureté :99.7%Couleur et forme :SolidMasse moléculaire :383.27JDTic
CAS :JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Formule :C28H39N3O3Couleur et forme :SolidMasse moléculaire :465.63JAK2-IN-7
CAS :JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.Formule :C26H33N7ODegré de pureté :99.54%Couleur et forme :SolidMasse moléculaire :459.59Ref: TM-T35900
1mg145,00€5mg354,00€10mg630,00€25mg1.301,00€50mg1.738,00€100mg2.357,00€1mL*10mM (DMSO)358,00€XMD-17-51 Trifluoroacetate
CAS :XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound that regulates protein kinases.Formule :C23H25F3N8O3Degré de pureté :99.65%Couleur et forme :SolidMasse moléculaire :518.49Ibrutinib Racemate
CAS :Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.Formule :C25H24N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :440.5ENMD-2076 tartrate
CAS :ENMD-2076 is an orally active kinase inhibitor. It also has antiangiogenic and antiproliferative mechanisms of action.Formule :C25H31N7O6Couleur et forme :SolidMasse moléculaire :525.56Nimotuzumab (powder)
CAS :Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.
Couleur et forme :LiquidHMBD-001
HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.
Couleur et forme :Odour LiquidImbotolimod
Imbotolimod, a humanized monoclonal antibody of the immunoglobulin G1-kappa class, exhibits both anti-ERBB2 and antineoplastic activities.Couleur et forme :Odour LiquidXMU-MP-3
CAS :XMU-MP-3 is a robust, non-covalent inhibitor of BTK, exhibiting exceptional potency with IC50 values of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation, respectively, in the presence of 10 μM ATP. Moreover, XMU-MP-3 elicits apoptosis.Formule :C27H27F3N8OCouleur et forme :SolidMasse moléculaire :536.563(3R,4S)-Tofacitinib
CAS :(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37TLC9995-0188
CAS :Tyrosine-protein kinase ABL, IC50: 1500 nMFormule :C16H15N5Couleur et forme :Yellow SolidMasse moléculaire :277.331PM-8002
PM-8002 is a bispecific antibody that targets PD-L1 and VEGF-A. It is applicable for research on solid tumors.
Couleur et forme :Odour LiquidDihydrodiol-Ibrutinib
CAS :PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A. 1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)Formule :C25H26N6O4Couleur et forme :SolidMasse moléculaire :474.521Olmutinib
CAS :Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFormule :C26H26N6O2SDegré de pureté :99.14%Couleur et forme :SolidMasse moléculaire :486.59Desidustat
CAS :Desidustat is an inhibitor of HIF hydroxylase.
Formule :C16H16N2O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :332.31Ref: TM-T5176
Produit arrêtéPF-03814735
CAS :PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.Formule :C23H25F3N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :474.48Duligotuzumab
CAS :Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.
Degré de pureté :95%Couleur et forme :Liquid3,3',4,4'-Tetrabromobiphenyl
CAS :Produit contrôléApplications 3,3',4,4'-Tetrabromobiphenyl is multi-persistent organic pollutants analyzed in breast milk of first time mothers. An environmental pollutant that affects copper and molybdenum metabolism in rats. Also, it is derived from 1-Bromo-2- nitrobenze (B686175), which is an organic building block used for the synthesis of various pharmaceutical compounds. It is an intermediate for the synthesis of novel Diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity.
References Tlustos, C., et al.: Organohalogen Compd., 75, 1185-1188 (2013); Salman, K. N., et al.: Environ. Sci. Pollut. R., 21, 6400-6409 (2014); Dao, P., et al.: Bioorg. Med. Chem. Lett., 23, 4552 (2013);Formule :C12H6Br4Couleur et forme :Off-White To Light BrownMasse moléculaire :469.79VEGFR-IN-1
CAS :VEGFR inhibitorFormule :C19H16ClN3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :337.8
